Although mutations in Kras are present in 21% of lung tumors, there is a high level of heterogeneity in phenotype and outcome among patients with lung cancer bearing similar mutations, suggesting that other pathways are important. Wnt/β-catenin signaling is a known oncogenic pathway that plays a well-defined role in colon and skin cancer; however, its role in lung cancer is unclear. We have shown here that activation of Wnt/β-catenin in the bronchiolar epithelium of the adult mouse lung does not itself promote tumor development. However, concurrent activation of Wnt/β-catenin signaling and expression of a constitutively active Kras mutant (KrasG12D) led to a dramatic increase in both overall tumor number and size compared with KrasG12D alone. Activation of Wnt/β-catenin signaling altered the KrasG12D tumor phenotype, resulting in a phenotypic switch from bronchiolar epithelium to the highly proliferative distal progenitors found in the embryonic lung. This was associated with decreased E-cadherin expression at the cell surface, which may underlie the increased metastasis of tumors with active Wnt/β-catenin signaling. Together, these data suggest that activation of Wnt/β-catenin signaling can combine with other oncogenic pathways in lung epithelium to produce a more aggressive tumor phenotype by imposing an embryonic distal progenitor phenotype and by decreasing E-cadherin expression.
Eugenia C. Pacheco-Pinedo, Amy C. Durham, Kathleen M. Stewart, Ashley M. Goss, Min Min Lu, Francesco J. DeMayo, Edward E. Morrisey
Title and authors | Publication | Year |
---|---|---|
HOPX: A Unique Homeodomain Protein in Development and Tumor Suppression
Caspa Gokulan R, Yap LF, Paterson IC |
Cancers | 2022 |
TLR/WNT: A Novel Relationship in Immunomodulation of Lung Cancer
Martín-Medina A, Cerón-Pisa N, Martinez-Font E, Shafiek H, Obrador-Hevia A, Sauleda J, Iglesias A |
International journal of molecular sciences | 2022 |
Loss of TET reprograms Wnt signaling through impaired demethylation to promote lung cancer development
Xu Q, Wang C, Zhou JX, Xu ZM, Gao J, Sui P, Walsh CP, Ji H, Xu GL |
Proceedings of the National Academy of Sciences | 2022 |
Iloprost requires the Frizzled-9 receptor to prevent lung cancer
Sompel K, Dwyer-Nield LD, Smith AJ, Elango A, Backos DS, Zhang B, Gross J, Ternyak K, Matsuda JL, Kopf K, Keith RL, Tennis MA |
iScience | 2022 |
EHMT2 methyltransferase governs cell identity in the lung and is required for KRAS G12D tumor development and propagation
Pribluda A, Daemen A, Lima AN, Wang X, Hafner M, Poon C, Modrusan Z, Katakam AK, Foreman O, Eastham J, Hung J, Haley B, Garcia JT, Jackson EL, Junttila MR |
eLife | 2022 |
Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines.
da Silva-Oliveira RJ, Gomes INF, da Silva LS, Lengert AVH, Laus AC, Melendez ME, Munari CC, Cury FP, Longato GB, Reis RM |
International journal of molecular sciences | 2022 |
Co-expression patterns explain how a basic transcriptional role for MYC modulates Wnt and MAPK pathways in colon and lung adenocarcinomas.
Kucherlapati MH |
Cell cycle (Georgetown, Tex.) | 2022 |
SOX9 maintains human foetal lung tip progenitor state by enhancing WNT and RTK signalling.
Sun D, Llora Batlle O, van den Ameele J, Thomas JC, He P, Lim K, Tang W, Xu C, Meyer KB, Teichmann SA, Marioni JC, Jackson SP, Brand AH, Rawlins EL |
The EMBO Journal | 2022 |
WNT5A-RHOA signaling is a driver of tumorigenesis and represents a therapeutically actionable vulnerability in small cell lung cancer
Kim KB, Kim DW, Kim Y, Tang J, Kirk N, Gan Y, Kim B, Fang B, Park JI, Zheng Y, Park KS |
Cancer research | 2022 |
IGF2BP3 is an essential N6-methyladenosine biotarget for suppressing ferroptosis in lung adenocarcinoma cells
Xu X, Cui J, Wang H, Ma L, Zhang X, Guo W, Xue X, Wang Y, Qiu S, Tian X, Miao Y, Wu M, Yu Y, Xu Y, Wang J, Qiao Y |
2022 | |
SMEK1 promotes lung adenocarcinoma proliferation and invasion by activating Wnt/β-catenin signaling pathway.
Chen D, Gao S, Gao F, Liu A, Li J, Li J, Liu Q |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2022 |